Bladder Cancer – Global Epidemiology Insights and Disease Burden Report (Top 32 Markets) – 2020 To 2040

 Bladder Cancer Epidemiology Insights

Thelansis’s “Bladder Cancer Global Epidemiology Insights and Disease Burden Report (Top 32 Markets) – 2020 To 2040″ provides an analysis of disease burden, characterized by disease definition, kidney biopsy cases, prevalence, incidence, diagnosed cases, severity, comorbidities, and clinical manifestations. Potential patient flow dynamics in disease burden are driven by shifts in demographic indicators and their correlation with age and gender distribution over time. Changes in the reported cases and long-term survival of patients may depend on diet, lifestyle, comorbid conditions, and the availability of interventions or therapies for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America).

⁠Bladder Cancer Overview

Bladder cancer is a common urothelial tract malignancy driven by risk factors like smoking and somatic mutations (FGFR3, TP53). Painless hematuria is the cardinal symptom, with diagnosis confirmed via cystoscopy and CT urography. The therapeutic landscape across all stages has been entirely transformed by immunotherapy and antibody-drug conjugates (ADCs). In high-risk, BCG-naive non-muscle-invasive disease (NMIBC), management endoscopically via transurethral resection is optimized by the approved addition of durvalumab to intravesical BCG. For BCG-unresponsive variants, the paradigm utilizes the IL-15 superagonist Anktiva plus BCG or systemic pembrolizumab. For muscle-invasive disease (MIBC), standard care has shifted from simple neoadjuvant cisplatin to advanced perioperative regimens, incorporating either durvalumab plus gemcitabine/cisplatin or the blockbuster combination of enfortumab vedotin (EV) plus pembrolizumab. In the metastatic setting, the combination of EV and pembrolizumab stands as the undisputed first-line standard of care, relegating traditional platinum chemotherapy with maintenance avelumab to a fallback strategy, while erdafitinib targets FGFR3-altered tumors. Long-term surveillance remains vital.

Market Definition:

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Deliverables format and updates*:

• Access to an interactive epidemiology platform with downloadable Excel and PPT files.
• Global findings
• G8 findings
• Regional findings
• Country-specific findings
• Others*: regular updates, customizations, epidemiologist support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the content. Countries, subpopulations, and years of forecast can be customized as per client requirements.

Key business questions answered:

• 20-year historical and forecast data (2020–2040)
• Disease definition based on globally accepted and latest criteria (e.g., ICD-10 codes)
• Granular patient population coverage by year and geography
• Detailed segmentation by age, gender, subpopulations, comorbidities, line of therapies, etc.
• Patient funnels
• Country comparisons
• Relevant clinical variables (e.g., staging/classification/severity)

Insights driven by robust research and estimates:

• Published literature (e.g., peer-reviewed journal articles, registries, national surveys)
• Primary market research with KOLs
• RWD analysis using claims and EHR datasets
• Proprietary mathematical models (e.g., incidence-survival model; incidence- recurrence/progression-survival model)

 

Read more: Bladder Cancer – Global Epidemiology Insights and Disease Burden Report (Top 32 Markets) – 2020 To 2040